Submit Content
Get the latest delivered to your inbox
Privacy Policy

African Research Foundation Partners With International Pharmaceutical Industry to Strengthen Capacity for Health Innovation in Africa

Published 09-28-21

Submitted by International Federation of Pharmaceutical Manufacturers & Associations

H3D-Foundation
H3D-Foundation

African research foundation partners with international pharmaceutical industry to strengthen capacity for health innovation in Africa

CAPE TOWN, South Africa and GENEVA, September 28, 2021 /3BL Media/ - H3D-Foundation (H3D-F) and the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) announced today a three-year partnership to strengthen capacity for health innovation in Africa. The two organizations will combine forces to focus on driving capacity strengthening for drug discovery and development in Africa by scaling existing initiatives and identifying new development opportunities for young and mid-career scientists in the region.

The COVID-19 pandemic has highlighted the urgent need to bolster Africa’s ability, including its drug innovation capabilities, to face future health emergencies. Africa only conducts approximately 2 percent of world research on new infections, despite shouldering a quarter of the global disease burden1. While the continent is better prepared now to contribute to new healthcare threats as they emerge compared to a few decades ago, the disease focus remains narrow and is often not fully aligned with regional priorities. According to H3D-F, a foundation established to reduce barriers for health innovation and actively support African researchers and centers within the field of drug discovery and related sciences, the continent is primed for progress but requires an integrated health innovation ecosystem, investment in robust infrastructure, technology platforms, a critical mass of skilled talent, and job creation.

“The University of Cape Town Holistic Drug Discovery & Development (H3D) centre is the only integrated drug discovery and development platform in Africa. Over the last 10 years, it has proven itself as a platform to develop world class infrastructure, talent, and health innovation that will contribute to improving lives not only in Africa, but all over the world. We are ready to take our work to the next level through partnership and collaboration with key organizations like IFPMA, strengthening capacity far beyond H3D,” said Kelly Chibale, Chairman and CEO of H3D-F and Founder and Director of H3D.

Africa now hosts over 250 research sites and 73 vaccine clinical trials, but there are many gaps to fill2. For example, less than 10 universities provide vaccinology courses and only two local universities engage in vaccine-related pre-clinical studies3. IFPMA’s role is to be an anchor partner to provide short- to mid-term support in increasing awareness of H3D-F activities to develop and strengthen the capacity of human resources for health innovation in Africa. It will facilitate networking and visibility across the innovation ecosystem through its membership and offer opportunities for collaboration from drug development to market. Shared aims of the organizations are to call attention to drug innovation and access in the region – key pillars to achieving the sustainable development goals and universal health coverage.

“Global product development research, driven by local needs, is pivotal to achieving shared global goals,” said Greg Perry, Assistant Director General of IFPMA. “Some of our partners, including Johnson and Johnson, MSD, and Novartis, already work with H3D. With H3D-F, now is the time to forge long-term relationships that lay the foundation for scientific coordination, communication, and discovery in Africa. IFPMA is proud to support H3D-F’s efforts".

The partnership was launched at an event on 28 September, for more details please visit the event page.

About the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)

IFPMA represents research-based pharmaceutical companies and associations across the globe. The research-based pharmaceutical industry’s two million employees research, develop, and provide medicines and vaccines that improve the life of patients worldwide. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

About H3D- Foundation (H3D-F)

H3D-F aims to position Africa as a global player in innovative pharmaceutical R&D by building infrastructure as well as the skills of African scientists and researchers. The Foundation further aims to serve as a convening platform and credible voice for evidence-based global health views. It was established in 2019 to build on the success of the H3D Centre’s capacity development programs, which include the Global Health Mentorship Program and the Grand Challenges Africa Drug Discovery Program, which engages more than 40 scientists in over six African countries.

For further information, please contact

Alacia Armstrong
Alacia.armstrong@uct.ac.za
+27 71 3346434

Abigail Jones
a.jones@ifpma.org
+32 475 41 09 76


1,2,3 African Union and Africa CDC. (2021). Discussion paper on Africa’s Vaccine Manufacturing for Health Security at the Conference on Expanding Africa’s Vaccine Manufacturing: https://africacdc.org/event/virtual-conference-expanding-africas-vaccine-manufacturing/.

International Federation of Pharmaceutical Manufacturers & Associations logo

International Federation of Pharmaceutical Manufacturers & Associations

International Federation of Pharmaceutical Manufacturers & Associations

The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) represents research-based pharmaceutical companies and associations across the globe. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community find solutions that improve global health.

Research-based pharmaceutical companies make a unique contribution to global health as innovators of life-saving and life-changing medicines and vaccines, which improved millions of lives around the world. Both IFPMA and its companies are involved in hundreds of partnerships, including the Access Accelerated initiative, a partnership of over 20 biopharmaceutical companies developing innovative and sustainable solutions to improve access to non-communicable disease (NCDs) treatment and care in low- and middle income countries. Access Accelerated also partners with the World Bank and the Union of International Cancer Control to help address the full spectrum of access barriers to NCD medicines. These partnerships involve the discovery of treatments that threaten health security or unduly put a burden on low-income countries, as well as support Universal Health Coverage (UHC) by expanding access to medicines and vaccines and strengthening health systems and in doing so, contribute to the Sustainable Development Goals (SDG 3 and SDG 17).

IFPMA hosts the Secretariat of the AMR Industry Alliance, a coalition of over 100 biotechnology, diagnostic, generics and research-based biopharmaceutical companies and trade associations that was formed to drive and measure industry progress to curb antimicrobial resistance. IFPMA also played a key role in establishing the AMR Action Fund, a ground-breaking initiative involving over 20 biopharmaceutical companies, that aims to bring 2-4 new antibiotics to patients by 2030.

Other initiatives supported by IFPMA include: The African Global Health Leaders Fellowship, the Africa Young Innovators for Health Award, and Fight the Fakes.

More from International Federation of Pharmaceutical Manufacturers & Associations

Join today and get the latest delivered to your inbox